Tilray: Schedule III Is Moving Forward, And The Stock Is Still Cheap

Tilray Brands' international medical-cannabis revenue grew 34%, led by Germany, the UK, Poland and Italy, making the segment its principal growth driver. U.S. regulatory progress supports the investment case, although price compression, the absence of GAAP profitability and free cash flow, and continuing dilution remain material risks. Underlying cash generation is improving, supporting a continued Buy view.

Analysis

The key valuation question is whether international growth can outrun declining realized pricing and corporate overhead before another equity raise. For TLRY, incremental revenue has limited equity value unless gross-margin dollars and operating cash conversion improve; otherwise, growth principally extends the time required to reach self-funding. The market should discount management's cash-generation framing until quarterly operating cash flow, capex, working-capital movements, and fully diluted share count demonstrate a durable inflection.

U.S. regulatory progress is likely a better earnings catalyst for scaled domestic operators than for TLRY: MSOS constituents such as GTBIF, CURLF, and TCNNF have greater direct exposure to 280E tax relief and state-level retail economics. That creates a relative-risk issue for TLRY—its regulatory narrative can lift the multiple in the near term, but it may underperform if investors rotate toward companies with more immediate EBITDA and cash-tax sensitivity. Conversely, a favorable German reimbursement or import-policy development could support TLRY's differentiated international premium over the next 6-12 months, provided price compression stabilizes.

Near term, this is primarily a sentiment and multiple trade around earnings and regulatory headlines, not a confirmed fundamental turnaround. Falsification is straightforward: exit a constructive view if international growth decelerates materially, gross margin fails to expand despite scale, or the diluted share count rises faster than revenue over the next two reporting periods. A sustained positive thesis requires evidence that international contribution profit—not revenue—can cover central costs without external capital.

Key Decisions for Investors

• Keep TLRY on a tactical watchlist rather than establish a core long before the next earnings release; initiate only if management shows sequential gross-margin expansion and positive operating cash flow excluding favorable working-capital swings. Risk/reward is unattractive if another at-the-market issuance is needed within 6 months.
• For a U.S. regulatory-upside expression over the next 1-3 months, prefer long MSOS versus short TLRY in equal dollar amounts. The trade monetizes greater 280E and domestic retail sensitivity at MSOS holdings; cover the short if Germany-specific policy or reimbursement news produces a material upward revision to TLRY international guidance.
• If holding TLRY, size it as a high-volatility event position and use the next two earnings reports as a hard catalyst window. Reduce exposure on any guidance that emphasizes revenue growth without contribution-margin, operating-cash-flow, or share-count targets.
• Monitor quarterly international revenue per unit, consolidated gross margin, cash burn, and diluted shares outstanding. A combination of stable pricing, margin expansion, and no meaningful dilution would justify reassessing TLRY as a 6-18 month recovery long; absent that, treat headline-driven rallies as opportunities to trim.